• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于研究冠状病毒感染和开发抗病毒药物和疫苗的动物模型。

Animal models for studying coronavirus infections and developing antiviral agents and vaccines.

机构信息

Guangdong Provincial Key Laboratory of Veterinary Pharmaceutics Development and Safety Evaluation, College of Veterinary Medicine, South China Agricultural University, Guangzhou, 510642, China.

Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Monash University, Clayton, Victoria 3168, Australia.

出版信息

Antiviral Res. 2022 Jul;203:105345. doi: 10.1016/j.antiviral.2022.105345. Epub 2022 May 21.

DOI:10.1016/j.antiviral.2022.105345
PMID:35605699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9122840/
Abstract

In addition to severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 has become the third deadly coronavirus that infects humans and causes the new coronavirus disease (COVID-19). COVID-19 has already caused more than six million deaths worldwide and it is likely the biggest pandemic of this century faced by mankind. Although many studies on SARS-CoV-2 have been conducted, a detailed understanding of SARS-CoV-2 and COVID-19 is still lacking. Animal models are indispensable for studying its pathogenesis and developing vaccines and antivirals. In this review, we analyze animal models of coronavirus infections and explore their applications on antivirals and vaccines.

摘要

除了严重急性呼吸综合征冠状病毒(SARS-CoV)和中东呼吸综合征冠状病毒(MERS-CoV),SARS-CoV-2 已成为第三种感染人类并导致新型冠状病毒病(COVID-19)的致命冠状病毒。COVID-19 已在全球范围内造成超过 600 万人死亡,这很可能是人类本世纪面临的最大的大流行疾病。尽管已经对 SARS-CoV-2 进行了许多研究,但人们对 SARS-CoV-2 和 COVID-19 的了解仍不充分。动物模型对于研究其发病机制以及开发疫苗和抗病毒药物是不可或缺的。在这篇综述中,我们分析了冠状病毒感染的动物模型,并探讨了它们在抗病毒药物和疫苗方面的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8ee/9122840/b4c8d6385c09/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8ee/9122840/bd427c4045e6/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8ee/9122840/3c6fdc3d5f16/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8ee/9122840/b4c8d6385c09/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8ee/9122840/bd427c4045e6/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8ee/9122840/3c6fdc3d5f16/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d8ee/9122840/b4c8d6385c09/gr3_lrg.jpg

相似文献

1
Animal models for studying coronavirus infections and developing antiviral agents and vaccines.用于研究冠状病毒感染和开发抗病毒药物和疫苗的动物模型。
Antiviral Res. 2022 Jul;203:105345. doi: 10.1016/j.antiviral.2022.105345. Epub 2022 May 21.
2
Potent 3CLpro inhibitors effective against SARS-CoV-2 and MERS-CoV in animal models by therapeutic treatment.在动物模型中,通过治疗给药,有效的 3CLpro 抑制剂对 SARS-CoV-2 和 MERS-CoV 有效。
mBio. 2024 Feb 14;15(2):e0287823. doi: 10.1128/mbio.02878-23. Epub 2023 Dec 21.
3
[Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].[2019冠状病毒病及严重急性呼吸综合征冠状病毒2的诊断、治疗、控制与预防:回归未来]
Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592. doi: 10.13345/j.cjb.200115.
4
Viral Infections of the Upper Airway in the Setting of COVID-19: A Primer for Rhinologists.新型冠状病毒病(COVID-19)背景下的上呼吸道病毒感染:鼻科医生的入门知识。
Am J Rhinol Allergy. 2021 Jan;35(1):122-131. doi: 10.1177/1945892420947929. Epub 2020 Aug 6.
5
Remdesivir against COVID-19 and Other Viral Diseases.瑞德西韦治疗 COVID-19 及其他病毒性疾病。
Clin Microbiol Rev. 2020 Oct 14;34(1). doi: 10.1128/CMR.00162-20. Print 2020 Dec 16.
6
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.严重急性呼吸综合征(SARS)、中东呼吸综合征(MERS)和严重急性呼吸综合征冠状病毒 2(COVID-19)治疗:专利述评。
Expert Opin Ther Pat. 2020 Aug;30(8):567-579. doi: 10.1080/13543776.2020.1772231. Epub 2020 Jun 7.
7
Molnupiravir and Its Antiviral Activity Against COVID-19.莫努匹韦及其抗 COVID-19 的抗病毒活性。
Front Immunol. 2022 Apr 4;13:855496. doi: 10.3389/fimmu.2022.855496. eCollection 2022.
8
The novel zoonotic COVID-19 pandemic: An expected global health concern.新型人畜共患的新冠疫情:一个意料之中的全球卫生问题。
J Infect Dev Ctries. 2020 Mar 31;14(3):254-264. doi: 10.3855/jidc.12671.
9
A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment.在新冠病毒保护和治疗的竞赛中,疫苗和治疗药物研发的最新成果。
J Evid Based Integr Med. 2021 Jan-Dec;26:2515690X211003727. doi: 10.1177/2515690X211003727.
10
Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries.新冠病毒疫苗研发和靶向治疗的现状:基础科学发现的影响。
Cardiovasc Pathol. 2021 Jan-Feb;50:107278. doi: 10.1016/j.carpath.2020.107278. Epub 2020 Sep 2.

引用本文的文献

1
Marmosets as models of infectious diseases.狨猴作为传染病模型。
Front Cell Infect Microbiol. 2024 Feb 23;14:1340017. doi: 10.3389/fcimb.2024.1340017. eCollection 2024.
2
In Vitro Combinatorial Activity of Direct Acting Antivirals and Monoclonal Antibodies against the Ancestral B.1 and BQ.1.1 SARS-CoV-2 Viral Variants.针对原始 B.1 和 BQ.1.1 SARS-CoV-2 病毒变异株的直接作用抗病毒药物和单克隆抗体的体外组合活性。
Viruses. 2024 Jan 23;16(2):168. doi: 10.3390/v16020168.
3
SARS-CoV-2 Aerosol and Intranasal Exposure Models in Ferrets.

本文引用的文献

1
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?奥密克戎:为何最新的 SARS-CoV-2 变体如此令人担忧?
J Virol. 2022 Mar 23;96(6):e0207721. doi: 10.1128/jvi.02077-21.
2
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern.口服蛋白酶抑制剂(PF-07321332)可保护叙利亚仓鼠免受高关注变异 SARS-CoV-2 病毒株的感染。
Nat Commun. 2022 Feb 15;13(1):719. doi: 10.1038/s41467-022-28354-0.
3
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
SARS-CoV-2 气溶胶和鼻腔暴露模型在雪貂中的应用。
Viruses. 2023 Nov 29;15(12):2341. doi: 10.3390/v15122341.
4
The Isolation and In Vitro Differentiation of Primary Fetal Baboon Tracheal Epithelial Cells for the Study of SARS-CoV-2 Host-Virus Interactions.用于研究 SARS-CoV-2 宿主-病毒相互作用的原代狒狒胎气管上皮细胞的分离和体外分化。
Viruses. 2023 Mar 28;15(4):862. doi: 10.3390/v15040862.
5
Ferrets: A powerful model of SARS-CoV-2.雪貂:SARS-CoV-2 的强大模型。
Zool Res. 2023 Mar 18;44(2):323-330. doi: 10.24272/j.issn.2095-8137.2022.351.
奥密克戎变异株的融合性和致病性减弱。
Nature. 2022 Mar;603(7902):700-705. doi: 10.1038/s41586-022-04462-1. Epub 2022 Feb 1.
4
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination.严重急性呼吸综合征冠状病毒2型奥密克戎变种对莫努匹拉韦、奈玛特韦及二者联用高度敏感。
Cell Res. 2022 Mar;32(3):322-324. doi: 10.1038/s41422-022-00618-w. Epub 2022 Jan 20.
5
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.用于新冠治疗和新冠病毒检测的单克隆抗体。
J Biomed Sci. 2022 Jan 4;29(1):1. doi: 10.1186/s12929-021-00784-w.
6
Caution required with use of ritonavir-boosted PF-07321332 in COVID-19 management.在新冠病毒疾病管理中使用利托那韦增强型PF-07321332时需谨慎。
Lancet. 2022 Jan 1;399(10319):21-22. doi: 10.1016/S0140-6736(21)02657-X.
7
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.第三次BNT162b2疫苗接种对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎感染的中和作用
N Engl J Med. 2022 Feb 3;386(5):492-494. doi: 10.1056/NEJMc2119358. Epub 2021 Dec 29.
8
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.免疫后血清对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎B.1.1.529变体的中和作用降低。
Lancet. 2022 Jan 15;399(10321):234-236. doi: 10.1016/S0140-6736(21)02844-0. Epub 2021 Dec 20.
9
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses.药物联合治疗作为对抗冠状病毒和其他新兴病毒的第一道防线。
mBio. 2021 Dec 21;12(6):e0334721. doi: 10.1128/mbio.03347-21.
10
SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance.严重急性呼吸综合征冠状病毒2型奥密克戎毒株表现出强大的免疫逃逸和病毒入侵能力。
Signal Transduct Target Ther. 2021 Dec 17;6(1):430. doi: 10.1038/s41392-021-00852-5.